Vyleesi receives FDA nod to treat women with low sexual desire
by Robert Herriman from Outbreak News Today on (#4HSJF)
The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. "There are women who, for no known reason, have reduced sexual desire that causes marked distress, and who can benefit from safe and effective pharmacologic treatment. Today's approval provides women with another treatment ["]
The post Vyleesi receives FDA nod to treat women with low sexual desire appeared first on Outbreak News Today.